Jump to any asset
849 assets, updated daily
Boston Scientific vs Medtronic plc
VS
Comparative Analysis
Boston Scientific (BSX) wins this head-to-head comparison against Medtronic (MDT) due to stronger recent earnings performance and a more favorable technical setup, despite MDT's larger market capitalization and higher median analyst target. BSX has demonstrated consistent positive earnings surprises in its most recent quarters, indicating operational strength that is not fully reflected in its current price. While MDT offers a dividend yield, BSX's current momentum and valuation metrics present a more compelling risk-reward profile for investors seeking capital appreciation. BSX's price action, though currently below its longer-term averages, shows signs of stabilizing near its 52-week low, suggesting potential for a rebound. In contrast, MDT is trading closer to its 52-week high but shows weaker momentum indicators. The key differentiator lies in BSX's ability to consistently beat earnings expectations, suggesting a more resilient business model in the current market environment.
Key Differentiator
The most significant differentiator between Boston Scientific (BSX) and Medtronic (MDT) is BSX's consistent ability to outperform earnings expectations, coupled with its more attractive valuation and potential for a technical rebound from its 52-week low. While MDT offers a dividend and a higher market cap, BSX's operational execution and current price action present a more compelling case for near-term upside.
Joint Outlook
Boston Scientific (BSX) has the potential for a significant recovery, driven by its attractive valuation, consistent earnings beats, and improving technical indicators as it consolidates near its 52-week low. A sustained break above its 50-day moving average ($46.54) could signal the start of a new uptrend. Medtronic (MDT) is expected to continue its more stable, albeit slower, growth trajectory, supported by its dividend and larger market presence. However, its current valuation and proximity to its 52-week high present a risk of stagnation or a moderate pullback if broader market sentiment shifts or if its growth rate falters.
Price Analysis Comparison
Valuation Metrics
| Metric | BSX | MDT |
|---|---|---|
| P/E Ratio | 17.02 | 21.50 |
| Market Cap | 61.93B | 113.18B |
| Price/Sales | 2.90 | 2.98 |
| Price/Book | 2.44 | 2.23 |
| EV/EBITDA | 12.83 | 12.62 |
| Dividend Yield | N/A | 3.23% |
Boston Scientific (BSX) trades at a P/E ratio of 17.02, which is lower than Medtronic's (MDT) P/E of 21.50, suggesting BSX is more attractively valued on a relative earnings basis. BSX's price is currently trading near its 52-week low of $41.39, indicating significant downside may have already been priced in. MDT, on the other hand, is trading closer to its 52-week high of $106.33, suggesting less immediate upside potential from current levels. BSX's price is currently below its 50-day ($46.54) and 200-day ($60.41) moving averages, signaling a downtrend, but its proximity to the 52-week low suggests a potential inflection point. MDT's price is also below its 50-day ($90.11) moving average but remains above its 200-day ($88.38) moving average, indicating a more mixed technical picture.
Profitability & Efficiency
| Metric | BSX | MDT |
|---|---|---|
| Rev. Growth (Qtly) | 7.50% | 13.70% |
| Profit Margin | 17.50% | 13.93% |
| Return on Equity | 15.34% | 10.65% |
| Return on Assets | 6.19% | 5.12% |
| Debt/Equity | 50.15 | 55.37 |
Boston Scientific (BSX) demonstrates superior profitability metrics compared to Medtronic (MDT). BSX boasts a net profit margin of 17.5% and a return on equity (ROE) of 15.34%, both significantly higher than MDT's net profit margin of 13.93% and ROE of 10.65%. BSX also shows a better return on assets (ROA) at 6.19% compared to MDT's 5.12%. These figures indicate that BSX is more efficient in converting revenue into profit and generating returns for its shareholders and on its asset base. While both companies operate within the healthcare sector, BSX's stronger margin and efficiency ratios suggest a stronger operational performance.
Earnings Reality Check
BSX
Last 5 Qs: BSX beat estimates 4x out of 5. Fell 2x after beats. (Sell the news?)
MDT
Last 4 Qs: MDT beat estimates 4x out of 4. Fell 2x after beats. (Sell the news?)
Technical Indicators
| Indicator | BSX | MDT |
|---|---|---|
| RSI (14) | 42.00 | 38.85 |
| 50-Day MA | $46.54 | $90.11 |
| 200-Day MA | $60.41 | $88.38 |
Boston Scientific (BSX) is exhibiting signs of bottoming, trading near its 52-week low and showing a RSI of 42, which is moving away from oversold territory. Its MACD is negative at -1.09, but the downward momentum appears to be decelerating. The stock is below its key moving averages (20-day EMA at $43.59, 50-day SMA at $46.54, 200-day SMA at $60.41), indicating a prevailing downtrend, but its current position suggests potential for a reversal. Medtronic (MDT) shows a weaker technical picture, with an RSI of 38.85 indicating bearish momentum and a MACD of -0.97, also suggesting downward pressure. MDT is trading below its 20-day EMA ($88.63) and 50-day SMA ($90.11), but remains slightly above its 200-day SMA ($88.38), presenting a mixed trend. The stochastic indicator for BSX is at 30.80, while MDT's is at 43.76, with both suggesting room for upward movement, but BSX's proximity to its low may offer a better risk-reward for a technical bounce.
AI Analyst Sentiment
Technical rating: based on current price action versus moving averages and momentum. This measures short-term chart trend, not analyst opinion or company fundamentals.
BSX
Technical Score: 55/100
MDT
Technical Score: 70/100
Analyst sentiment favors both Boston Scientific (BSX) and Medtronic (MDT), with a majority of ratings leaning towards 'Buy' or 'Strong Buy'. BSX has a median analyst target price of $60, suggesting approximately 40.4% upside potential from its current price of $42.73. MDT has a higher median analyst target of $106, implying about 19.8% upside from its current price of $88.48. Despite MDT's higher median target, BSX's analyst consensus is more heavily weighted towards 'Strong Buy' (8) and 'Buy' (17) compared to MDT's (3 Strong Buy, 16 Buy). This suggests a stronger conviction among analysts for BSX's potential recovery, even though MDT is perceived to have a higher ceiling by some.
Note: While MDT shows stronger short-term technical momentum (Buy 70/100), the AI comparative analysis favors BSX (Hold 55/100) based on its overall trend structure, fundamentals, and risk-adjusted outlook.
Risk Stratification
| Metric | BSX | MDT |
|---|---|---|
| Beta (Volatility) | 0.58 | 0.57 |
| Sharpe Ratio | -0.84 | 0.10 |
Boston Scientific (BSX) faces the primary risk of its current downtrend continuing, potentially pushing the stock below its 52-week low if market conditions deteriorate or specific company news proves negative. The stock's significant drop from its 52-week high of $105.65 to its current price of $42.73 highlights its volatility and the potential for substantial capital loss. Medtronic (MDT) faces the risk of its valuation becoming a headwind, as its P/E ratio is higher and it is trading closer to its 52-week high. A slowdown in its revenue growth or a miss on future earnings expectations could lead to a sharp correction, given its current premium valuation. Also, its slightly lower profitability margins compared to BSX could be a concern if the company faces margin pressure.
Comparative ProTips
- Consider BSX for its value and potential technical rebound, especially if it holds its 52-week low.
- Monitor MDT's ability to maintain its premium valuation and dividend payout amidst potential market shifts.
- Given BSX's stronger profitability margins, it may be better positioned to weather economic downturns than MDT.
Monte Carlo Projection (10yr)
Actionable Trade Plans
Compare entry, exit, and risk management levels for both assets
Select Your Trade Bias
Risk Tolerance
Conservative
3%
Aggressive
Portfolio Value
$
✎
Position Size: $200 - $300 per asset
BSX
Current: $42.73
ENTRY ZONES
Conservative
$40.59
Aggressive
$42.73
RISK MANAGEMENT
STOP LOSS
$39.38
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$42.62
+10%
$44.65
+15%
$46.68
MDT
Current: $88.48
ENTRY ZONES
Conservative
$84.06
Aggressive
$88.48
RISK MANAGEMENT
STOP LOSS
$81.53
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$88.26
+10%
$92.46
+15%
$96.66
Calculate Your Trade
Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. Identifying the stronger asset is based on relative strength (RS) and technical convergence. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss. Note: The AI favored BSX based on price momentum. This is valid for the specified timeframe only. While MDT currently shows the stronger short-term technical score (70 vs 55), the AI favors BSX on the factors above rather than today's technical setup.
Frequently Asked Questions
Which is a better buy, BSX or MDT?+
BSX is currently a better buy due to its more attractive valuation (P/E 17.02 vs 21.50), consistent earnings beats, and potential for a technical rebound from its 52-week low. MDT offers a dividend yield but trades at a higher valuation with less compelling technical momentum.
What are the key risks for BSX vs MDT?+
BSX's main risk is the continuation of its downtrend and failure to rebound from its 52-week low. MDT's primary risks include its higher valuation potentially facing a correction if growth slows, and its slightly lower profitability margins.
How do BSX and MDT compare on profitability?+
BSX is more profitable, with a net profit margin of 17.5% and ROE of 15.34%, compared to MDT's 13.93% net profit margin and 10.65% ROE.
How do the P/E ratios compare between BSX and MDT?+
BSX has a P/E ratio of 17.02, which is lower than MDT's P/E ratio of 21.50, indicating BSX is cheaper on an earnings basis.
What do analysts say about BSX and MDT?+
Analysts are largely positive on both, but BSX has a higher concentration of 'Strong Buy' ratings and a median target price suggesting greater potential upside relative to its current price.
Which stock has better recent earnings performance?+
BSX has a more consistent record of positive earnings surprises in its last three quarters, indicating stronger operational execution compared to MDT, which had one very large surprise but also a price drop after a recent earnings report.